Literature DB >> 17049430

The significance of the site of recurrence to subsequent breast cancer survival.

A Imkampe1, S Bendall, T Bates.   

Abstract

AIM: To investigate differences in the 3-year survival of patients with recurrent breast cancer dependent on recurrence site.
METHODS: The study was a review of 294 patients from a breast cancer database, who were treated for operable breast cancer and subsequently developed a recurrence between 1989 and 2003. Patients were divided into four groups according to the site of first recurrence (local, lymph node, bone or visceral). Breast Cancer Specific Survival (BCSS) was compared using Kaplan-Meier life table analysis and the log rank test.
RESULTS: Patient and tumour characteristics were comparable between the four groups. Survival rates between the recurrence site groups were significantly different. Patients in whom first recurrence was local had the best prognosis with a 3-year BCSS of 83% compared to 33% for patients with first node recurrence (p<0.001), 23% for patients with first bone recurrence (p=0.03) and 13% for patients with first visceral recurrence (p=0.004).
CONCLUSION: Survival of patients with recurrent breast cancer is associated with the site of first recurrence. The prognosis from recurrence is progressively worse with local, regional, bone and visceral metastasis.

Entities:  

Mesh:

Year:  2006        PMID: 17049430     DOI: 10.1016/j.ejso.2006.09.005

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  12 in total

1.  Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.

Authors:  Siker Kimbung; Anikó Kovács; Pär-Ola Bendahl; Per Malmström; Mårten Fernö; Thomas Hatschek; Ingrid Hedenfalk
Journal:  Mol Oncol       Date:  2013-10-14       Impact factor: 6.603

2.  The Impact of Primary Tumor Surgery on Survival in HER2 Positive Stage IV Breast Cancer Patients in the Current Era of Targeted Therapy.

Authors:  Ross Mudgway; Carlos Chavez de Paz Villanueva; Ann C Lin; Maheswari Senthil; Carlos A Garberoglio; Sharon S Lum
Journal:  Ann Surg Oncol       Date:  2020-03-10       Impact factor: 5.344

3.  Automated CT-based analysis to detect changes in the prevalence of lytic bone metastases from breast cancer.

Authors:  T Skrinskas; M Clemons; O Freedman; I Weller; C M Whyne
Journal:  Clin Exp Metastasis       Date:  2008-10-22       Impact factor: 5.150

4.  Pretreatment 18F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.

Authors:  Chengcheng Gong; Guang Ma; Xichun Hu; Yingjian Zhang; Zhonghua Wang; Jian Zhang; Yannan Zhao; Yi Li; Yizhao Xie; Zhongyi Yang; Biyun Wang
Journal:  Oncologist       Date:  2018-08-06

5.  Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents.

Authors:  C Le Tourneau; V Servois; V Diéras; L Ollivier; P Tresca; X Paoletti
Journal:  Br J Cancer       Date:  2012-01-26       Impact factor: 7.640

6.  Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.

Authors:  Joachim Diessner; Manfred Wischnewsky; Tanja Stüber; Roland Stein; Mathias Krockenberger; Sebastian Häusler; Wolfgang Janni; Rolf Kreienberg; Maria Blettner; Lukas Schwentner; Achim Wöckel; Catharina Bartmann
Journal:  BMC Cancer       Date:  2016-05-12       Impact factor: 4.430

7.  Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.

Authors:  Jenny Stenström; Ingrid Hedenfalk; Catharina Hagerling
Journal:  Breast Cancer Res       Date:  2021-02-18       Impact factor: 6.466

8.  Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis.

Authors:  Joyce O'Shaughnessy; William J Gradishar; Paul Bhar; Jose Iglesias
Journal:  Breast Cancer Res Treat       Date:  2013-04-06       Impact factor: 4.872

9.  Breast cancer pathology, receptor status, and patterns of metastasis in a rural appalachian population.

Authors:  Linda Vona-Davis; David P Rose; Vijaya Gadiyaram; Barbara Ducatman; Gerald Hobbs; Hannah Hazard; Sobha Kurian; Jame Abraham
Journal:  J Cancer Epidemiol       Date:  2014-01-09

10.  Cryo-Assisted Resection En Bloc, and Cryoablation In Situ, of Primary Breast Cancer Coupled With Intraoperative Ultrasound-Guided Tracer Injection: A Preliminary Clinical Study.

Authors:  Nikolai N Korpan; Kecheng Xu; Philipp Schwarzinger; Masashi Watanabe; Gerhard Breitenecker; Le Pivert Patrick
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.